Mirati Therapeutics Inc logo

MRTX

Mirati Therapeutics Inc

$78.47

Earnings Summary

Revenue
$5.36Mn
Net Profits
$-176.45Mn
Net Profit Margins
-3290.66%

Highlights

Revenue:

Mirati Therapeutics Inc’s revenue jumped +Inf% since last year same period to $5.36Mn in the Q2 2022. On a quarterly growth basis, Mirati Therapeutics Inc has generated 656.28% jump in its revenue since last 3-months.

Net Profits:

Mirati Therapeutics Inc’s net profit fell -6.11% since last year same period to $-176.45Mn in the Q2 2022. On a quarterly growth basis, Mirati Therapeutics Inc has generated 6.34% jump in its net profits since last 3-months.

Net Profit Margins:

Mirati Therapeutics Inc’s net profit margin jumped NaN% since last year same period to -3290.66% in the Q2 2022. On a quarterly growth basis, Mirati Therapeutics Inc has generated 87.62% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Mirati Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-3.49
EPS Estimate Current Year
-3.49

Highlights

EPS Estimate Current Quarter:

Mirati Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -3.49 - a 0% jump from last quarter’s estimates.

EPS Estimate Current Year:

Mirati Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -3.49.

Key Ratios

Key ratios of the Mirati Therapeutics Inc post its Q2 2022 earnings

Return on Assets (ROA)
-0.3
Return on Equity (ROE)
-0.58
Dividend Per Share (DPS)
0

Highlights

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Mirati Therapeutics Inc’s return on assets (ROA) stands at -0.3.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Mirati Therapeutics Inc’s return on equity (ROE) stands at -0.58.

Dividend Per Share (DPS):

Mirati Therapeutics Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-04
-3.49
-3.4
2.58%

Company Information

Mirati Therapeutics is a late-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. Mirati is using its scientific expertise to develop novel solutions in two registration-enabling programs: adagrasib (MRTX849), an investigational small molecule, potent and selective KRAS G12C inhibitor, as monotherapy and in combination with other agents, and sitravatinib, an investigational spectrum-selective inhibitor of receptor tyrosine kinases in combination with checkpoint inhibitor therapies. Mirati is also advancing its differentiated preclinical portfolio, including MRTX1133, an investigational KRAS G12D inhibitor, and other oncology discovery programs. Unified for patients, Mirati's vision is to unlock the science behind the promise of a life beyond cancer.

Organisation
Mirati Therapeutics Inc
Headquarters
San Diego, California, US
Employees
200
Industry
Health Technology
CEO
Charles Baum